Michael Gunn
Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
About
Dr. Michael Gunn is a Professor at Duke University in the United States. His research focuses on nonclassical monocytes and their role in pulmonary vascular remodeling and pulmonary hypertension, as well as brain immunology and immunotherapy in brain tumors. His recent publications reflect his expertise in these critical areas of study.
Articles (9)
Viral myocarditis can lead to dilated cardiomyopathy in adults, yet the molecular mechanisms that induce cardiac inflammation in viral myocarditis remain unclear. β-Arrestins are scaffolding proteins that mediate intracellular signaling during viral infection. We demonstrated that cardiomyocyte β-arrestins are necessary for immune cell recruitment, induction of cardiac apoptosis, and cGAS-STING pathway activation during acute coxsackievirus B3 infection. Targeting β-arrestins appears to decrease the inflammatory response in acute viral myocarditis.
Year:
2026
IFN-β induction after TLR1/2 stimulation associates with PBMC ELISpot responses to Fluzone, PHA, and CEFT (cytomegalovirus, EBV, Fluzone, and Tetanus peptide pool). A, ELISpot SFU after each indicated stimulant ( n = 77 CEFT, n = 79 Fluzone, n = 82 for others). B, Cell type–specific PBMC densities as a percentage of live single cells (bottom) separated by median IFN-β response after TLR1/2 stimulation ( n = 106, PRIME study). A and B, P values are from unpaired t test; mean + SEM is shown. C, Correlation (Spearman r ) of each indicated PBMC (ELISpot), serum (ELISA), or sip-T product metric (CD54 upreg and TNC) output with fold mock IFN-β values after TLR1/2 stimulation; (*) indicates FDR adjusted Q
Year:
2024
Mounting evidence links systemic innate immunity with cancer immune surveillance. In advanced metastatic castration-resistant prostate cancer (mCRPC), Black patients have been found to have increased inflammatory markers and longer survival after sipuleucel-T (sip-T) therapy, an FDA-approved, autologous cell therapy. We hypothesized these differences may be explained by previously reported ancestral differences in pattern recognition receptor signaling, which broadly governs innate inflammation to control adaptive immune cell activation, chemotaxis, and functionality. We discovered that peripheral blood mononuclear cell IFN-β responses to Toll-like receptor 1/2 (TLR1/2), a sensor of bacterial and gut microbiome constituents, associated with significantly longer survival after sip-T therapy in two separate cohorts of men with mCRPC (discovery cohort: n = 106, HR = 0.12; P = 0.019; validation cohort: n = 28, HR P = 0.047). Higher IFN-β induction after TLR1/2 stimulation was associated with lower HRs than biomarkers of vaccine potency and other prognostic factors in mCRPC. TLR1/2-dependent cytokine induction was stronger in Black individuals (1.2-fold higher for IFN-β; P = 0.04) but was associated with survival independently of race or numbers of vaccine-induced tumor antigen–specific T cells. IFN-β responses to TLR1/2 signaling correlated with increased numbers of IFN-γ producing T cells after broad, tumor antigen–independent stimulation. Thus, peripheral innate immunity differs by race, may predict survival after sip-T, and associates with peripheral T-cell functionality in men with mCRPC. Significance: The identification of factors that determine successful cancer immunotherapy, particularly in refractory tumor types like mCRPC, is urgently needed: both to identify patients that may benefit from such therapies and to uncover routes to sensitize patients with cancer to immunotherapy. Our work links functional peripheral immune responses with race and survival after cellular immunotherapy in men with mCRPC.
Year:
2024
TLR1/2 responses associate with post–sip-T survival independent of race and TLR1/2 SNP status. A–C, Survival stratified by race in the merged PRIME and KCI cohorts ( A ), PRIME cohort alone ( B ), or KCI cohort alone ( C ). D and E, Survival of White ( D ) or Black ( E ) patients from the merged (PRIME and KCI) cohorts stratified by respective cohort median (PRIME or KCI) IFN-β induction after TLR1/2 stimulation. F and G, Survival of the PRIME cohort (TLR1 SNP genotyping was not performed in the KCI cohort) stratified by TLR1 602 I/I or I/S vs. TLR1 602 S/S for all races ( F ) or for White patients ( G ). H and I, Survival of patients with TLR1 602 I/I or I/S SNP ( H ) or TLR 602 S/S ( I ) stratified by median IFN-β induction after TLR1/2 stimulation. HRs and 95% CI are from the Mantel–Haenszel test; P values are from the Mantel–Cox log-rank test. See Supplementary Fig. S7 for extended data.
Year:
2024
Stronger IFN-β responses to TLR1/2 stimulation associates with longer survival after sip-T therapy. A, HRs ± 95% CIs from a Cox proportional hazards model comparing induction of each cytokine (fold mock control) after TLR1/2 stimulation with PAM 3 CSK 4 for PRIME cohort (left) or KCI cohort (right) vs. survival; *, P B, Survival of patients tested for TLR1/2 responsiveness stratified by median IFN-β induction for PRIME (left) and KCI (right) cohorts; P values are from Mantel–Cox test, HR and 95% CIs are from Mantel–Haenszel test. C, Mean z -scores normalized for each cytokine and treatment were computed for the combined cohort of patients (PRIME and KCI, n = 108), excluding patients that were censored prior to 1,000 days due to incomplete follow-up. Z -scores for patients surviving >1,000 days ( n = 47) are shown and reflect enrichment/depletion relative to the broader cohort; asterisk indicates FDR adjusted (within each stimulant group) t test Q D, Fold mock treated MFI values for IFN-β after treatment with TLR1/2 stimulation comparing patients surviving 1,000 days from PRIME (top) or KCI (bottom) subcohorts from C ; P values are from unpaired t test and mean + SEM is shown. E, Cox proportional hazards model derived HRs ±95% CI and P values for indicated prognostic features and IFN-β. PSA values were not available for two patients, which were excluded from these analyses ( n = 104). See Supplementary Figs. S2 and S3 for extended data. MFI, mean fluorescence intensity.
Year:
2024
Study design and in vitro responsiveness of PBMCs from patients with mCRPC to PRR agonist prior to sip-T treatment. A, Banked pretreatment PBMCs from the PRIME sip-T discovery cohort ( n = 106) or KCI validation cohort ( n = 28) were subjected to DNA isolation, flow cytometry, and/or testing in an in vitro stimulation assay. Two hundred thousand PBMCs per well were plated and treated with no stimulation (mock) or stimulation (stim) with TLR1/2 (PAM 3 CSK 4 ), TLR4 (LPS), MDA5 (Poly I:C-LyoVec), or T-cell [anti (α)-CD3/28 antibodies] after 24 hours of culture. B–D, Supernatant cytokine release was measured after in vitro stimulation. B, Principal component analyses colored by treatment using raw MFI values for each analyte, each data point represents a single patient. C, Box and whisker plots (Boxes: median ± 25%–75% quartiles, whiskers = range) of fold mock MFI values for each cytokine in the PRIME study ( n = 106), each data point represents a single patient. D, Heatmaps of log (fold mock control) values are shown for the PRIME and KCI (validation) cohorts; asterisks denote FDR adjusted Q t test vs. 0 (no induction). MFI, mean fluorescence intensity.
Year:
2024
Black race and TLR1-602I SNP associate with stronger responses to TLR1/2 stimulation. A, Supernatant cytokine release separated by Black ( n = 15) vs. White ( n = 91) for each stimulation normalized to fold mock treatment control in the PRIME study; (*) Mann–Whitney test P B, TLR1-602 genotypes for each patient with sufficient DNA ( n = 88 White; n = 15 Black) were tested by PCR-RFLP; percentages of I/I or I/S vs. S/S by race are shown. C, Mean fold mock control cytokine induction by genotype is shown for each stimulus; asterisks indicate significant FDR-corrected unpaired t tests Q D, Mean fold mock control TLR1/2 induced cytokine induction by genotype for White vs. Black (all I/I or I/S); FDR-adjusted unpaired t test Q E, Heatmaps depict −log ( P values) from comparisons in B (cytokine induction by race) or C (cytokine induction by TLR1 SNP status) for each cytokine and treatment. See Supplementary Fig. S6 for extended data.
Year:
2024
Year:
2020
Year:
2020
Collaborators (9)
Andrew Armstrong
Professor
Duke Cancer Institute
Haoran Jiang
Duke University School of Medicine
Frank Cackowski
Assistant Professor
Karmanos Cancer Institute
Michael Brown
Assistant Professor
Duke University
Julie Boerner
Associate Professor
Wayne State University
Wei Chen
Professor
Wayne State University
Lawrence G. Lum
Professor of Medicine
University of Virginia
Elisabeth I. Heath
Wayne State University School of Medicine
Archana Thakur
Associate Professor
University of Virginia
Make your next move.
Prepare your application
Review drafts before you send them.